Paper Details

  1. Home
  2. Paper Details

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Author: ArningMichael B, FahlkeJörg, GellertKlaus, HartmannJörg Thomas, HinkeAxel, HochhausAndreas, NeuhausPeter, NiedergethmannMarco, OettleHelmut, RidwelskiKarsten, RiessHanno, SinnMarianne, ZülkeCarl

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adjuvant gemcitabine treatment for 6 months compared with observation alone resulted in increased overall survival and disease-free survival in patients with macroscopic complete removal of pancreatic cancer.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: The prognosis for patients with pancreatic cancer is poor, even after resection with curative intent. Gemcitabine-based chemotherapy is standard treatment for advanced pancreatic cancer, but its effect on survival in the adjuvant setting has not been demonstrated. OBJECTIVE: To analyze ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.2013.279201

データ提供：米国国立医学図書館（NLM）

Gemcitabine for Pancreatic Cancer: A Beacon of Hope

Pancreatic cancer is a particularly challenging disease, often with a poor prognosis. This randomized trial investigated the efficacy of adjuvant gemcitabine chemotherapy in patients who had undergone complete surgical removal of pancreatic cancer. The researchers aimed to determine whether gemcitabine could improve disease-free survival and overall survival in this patient population.

Gemcitabine: A Promising Adjuvant Therapy

The trial's results revealed a significant benefit for patients treated with adjuvant gemcitabine. The median disease-free survival was significantly longer in the gemcitabine group compared to the observation group. Furthermore, gemcitabine treatment resulted in a significant improvement in overall survival, with a longer 5-year and 10-year survival rate in the gemcitabine group. These findings provide strong evidence supporting the use of gemcitabine as adjuvant therapy for patients with resected pancreatic cancer.

Hope for a Better Future

This study offers a ray of hope for patients diagnosed with pancreatic cancer. The findings demonstrate the potential of adjuvant gemcitabine to significantly improve outcomes and extend survival time. These results emphasize the importance of ongoing research to develop even more effective treatments for this challenging disease.

Dr.Camel's Conclusion

This groundbreaking trial sheds light on the potential of gemcitabine as a powerful tool in the fight against pancreatic cancer. The researchers' findings offer hope for patients and their families, demonstrating the impact of adjuvant therapy in improving survival outcomes. This study serves as a testament to the relentless pursuit of innovative treatments for this challenging disease.

Date :
  1. Date Completed 2013-10-31
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

24104372

DOI: Digital Object Identifier

10.1001/jama.2013.279201

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.